Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck

Purpose: We sought to evaluate the efficacy and safety of the combination of cetuximab (Cmab) and paclitaxel (PTX) in patients with squamous cell carcinoma of the head and neck (SCCHN) who had unresectable recurrent or metastatic (R/M) disease after platinum-based chemoradiotherapy.Materials and Met...

Full description

Bibliographic Details
Main Authors: Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Yuri Ueda, Shinya Uozumi, Makoto Tahara
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-08-01
Series:Frontiers in Oncology
Subjects:
paclitaxel
cetuximab
chemoradiotherapy
platinum-refractory
squamous cell carcinoma of the head and neck
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00339/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2018.00339/full

Similar Items